Results 141 to 150 of about 196,164 (338)

Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa

ClinicoEconomics and Outcomes Research, 2020
Ammar Almaaytah1,2 1Faculty of Pharmacy, Middle East University, Amman, Jordan; 2Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, JordanCorrespondence: Ammar Almaaytah Tel +962777658820Email aalmaaytah@meu.edu.joIntroduction ...
Almaaytah A
doaj  

EBV-reactivation and posttransplant lymphoproliferative disorder treated with rituximab [PDF]

, 2013
Vikas Dua, Satya Prakash Yadav
openalex   +1 more source

diagnostic value of anti-rituximab Ab in Iraqi patient with chronic lymphocytic leukemia

, 2022
Iqbal Muaafi Abdullah, Yaseen M. Taher, Alaa Fadhel Alwan, Mohammed M. Al-Ani   +3 more
openalex   +2 more sources

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial

BMJ Open
Introduction Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. Rituximab is now recommended as first-line therapy for membranous nephropathy.
Céline Fernandez, Marion Cremoni, Laurent Bailly, Kevin Zorzi, Vesna Brglez, Barbara Seitz-Polski, Maxime Teisseyre, Alexandre Destere, Sylvain Benito   +8 more
doaj   +1 more source

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial [PDF]

Lexy Sorrell, Toby A. Eyre, Mats Jerkeman, Simon Rule, Dave Wright, Cathy Burton, Mark Bishton, Andrew Davies, Christopher McNamara, Kristina Sonnevi, Jon Riise, Christian Bjørn Poulsen, Ingemar Lagerlöf, Ingrid Glimelius, Karin Fahl Wader, David Lewis   +15 more
openalex   +1 more source

Rituximab for Acquired Hemophilia A in the Setting of Bullous Pemphigoid [PDF]

, 2022
Maria C Bell
openalex   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source